Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoVVac study of COVID-19 vaccine immune responses in immunocompromised and healthy adults
2021-001040-10Phase 4Completed
- Sponsor
- Medical University of Graz
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of RH109 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Medical University of Graz. Primary endpoint: Seroconversion after second vaccination. Started Mar 2021; status: completed.
02
Drugs
RH109
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-001040-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001040-10.